- Home
- TSN vs BIIB Comparison
TSN vs BIIB Comparison
Compare TSN & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSN
- BIIB
- Stock Information
- Founded
- TSN 1935
- BIIB 1978
- Country
- TSN United States
- BIIB United States
- Employees
- TSN N/A
- BIIB N/A
- Industry
- TSN Meat/Poultry/Fish
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TSN Consumer Staples
- BIIB Health Care
- Exchange
- TSN Nasdaq
- BIIB Nasdaq
- Market Cap
- TSN 19.8B
- BIIB 18.8B
- IPO Year
- TSN N/A
- BIIB 1991
- Fundamental
- Price
- TSN $56.16
- BIIB $131.20
- Analyst Decision
- TSN Hold
- BIIB Buy
- Analyst Count
- TSN 8
- BIIB 26
- Target Price
- TSN $62.63
- BIIB $194.95
- AVG Volume (30 Days)
- TSN 4.0M
- BIIB 1.7M
- Earning Date
- TSN 05-05-2025
- BIIB 05-01-2025
- Dividend Yield
- TSN 3.56%
- BIIB N/A
- EPS Growth
- TSN N/A
- BIIB 26.39
- EPS
- TSN 2.57
- BIIB 10.12
- Revenue
- TSN $53,615,000,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- TSN $2.40
- BIIB N/A
- Revenue Next Year
- TSN $2.01
- BIIB N/A
- P/E Ratio
- TSN $21.87
- BIIB $12.83
- Revenue Growth
- TSN 1.39
- BIIB 1.59
- 52 Week Low
- TSN $53.61
- BIIB $110.04
- 52 Week High
- TSN $66.88
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- TSN 44.70
- BIIB 59.82
- Support Level
- TSN $55.17
- BIIB $123.97
- Resistance Level
- TSN $57.05
- BIIB $132.94
- Average True Range (ATR)
- TSN 0.89
- BIIB 3.49
- MACD
- TSN 0.17
- BIIB 1.04
- Stochastic Oscillator
- TSN 66.42
- BIIB 88.37
About TSN Tyson Foods Inc.
Tyson Foods is a protein-focused food producer, selling raw chicken, beef, pork, and prepared foods. Chicken and beef are its two largest segments, each composing about one third of US sales. Prepared foods constituted 18% of fiscal 2024 sales and include brands like Tyson, Jimmy Dean, Hillshire Farm, Ball Park, and Sara Lee. However, most of these are in product categories rife with competition where Tyson does not have a massive market share lead. Tyson sells some products overseas, but the international segment accounts for just 4% of total revenue. The company is an active acquirer, with more recent years' purchases focused on international and food-service markets.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.